The pharmaceutical industry is struggling with the concept of disclosing financial ties with doctors in Australia and Europe amid preparations for the implementation of the Sunshine Act in the U.S., Ed Silverman writes. The increased disclosure of financial ties was endorsed recently by the Australian Medical Association, but its code is being criticized for faults such as slow progress and the small fines for failure to comply, he writes. Meanwhile, drugmakers must disclose the type of relationship they have with doctors under the European Federation of Pharmaceutical Industries and Associations' voluntary code of "transfers of value," although it also has its shortcomings, he writes.

Full Story:

Related Summaries